Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Accutest Research Laboratories (I) Pvt. Ltd. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The goal of this clinical study is to assess the relative bioavailability of Amlodipine for Oral Solution 5 mg of Brillian Pharma Inc. under fasting and fed conditions versus reference product Norvasc 5 mg tablets of Pfizer Labs under fasting in normal, healthy, adult, male,
Primary Objective:
Secondary Objective:
To monitor the safety and tolerability of a single oral dose of investigational medicinal products (IMPs).
A total of 24 healthy, adult, male and female human volunteers will be enrolled.
Excluding the screening period, the duration of the clinical phase will be approximately 50 days including a washout period of at least 21 days for each study period.
This study is being conducted in healthy, adult, human subjects under fasting and fed conditions as per USFDA and NMPA guidelines. The present study will be conducted to assess the relative bioavailability of the test product versus the reference product under fasting conditions. The study also assesses the effect of food on the bioavailability of Amlodipine FD-POS 5 mg (Powder in a Unit-dose container) product.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| T1 Fasting | Experimental | Giving test product under fasting condition |
|
| T2 Fed | Experimental | Giving test product under fed condition |
|
| R Fasting | Active Comparator | Giving reference product under fasting condition |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Amlodipine Freeze-Dried Powder for Oral Solution 5 mg | Drug | Amlodipine Oral Solution 5 mg is given to T1 Fasting and T2 Fed |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cmax | Maximum observed drug concentration during the study | 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 12, 14, 16, 20, 24, 48, 60, 72, 96, 120, 144 hours post dose |
| AUC0-t | Area under the plasma concentration-time curve measured to the last quantifiable concentration, using the linear trapezoidal rule. | 50 days |
| AUC0-inf | AUC0-t plus additional area extrapolated to infinity, calculated using the formula AUC0-t + Ct/Kel , where Ct is the last measurable drug concentration and Kel is the elimination rate constant. | 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 12, 14, 16, 20, 24, 48, 60, 72, 96, 120, 144 hours post dose |
| Measure | Description | Time Frame |
|---|---|---|
| Tmax | Time to observe maximum drug concentration. If the maximum value occurs at more than 1 time point, Tmax is defined as the first time point with this value. | 6 days |
| AUC0-t/AUC0-inf | Ratio of AUC0-t and AUC0-inf |
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pratikkumar Dilipbhai Asari, M.D. | Accutest Research Laboratories (I) Pvt. Ltd. | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Accutest Research Laboratories (I) Pvt. Ltd. | Vadodara | Gujarat | 390016 | India |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006973 | Hypertension |
| D003324 | Coronary Artery Disease |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
Not provided
Not provided
| ID | Term |
|---|---|
| D012996 | Solutions |
| D017311 | Amlodipine |
| ID | Term |
|---|---|
| D004364 | Pharmaceutical Preparations |
| D004095 | Dihydropyridines |
| D011725 | Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
Not provided
Not provided
A Randomized, Open Label, Balanced, Three Treatment, Three period, Three Sequence, Single Dose, Crossover design.
Not provided
Not provided
Not provided
Not provided
| Norvasc 5 mg tablets of Pfizer Labs | Drug | Norvasc 5 mg is given to R Fasting |
|
|
| 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 12, 14, 16, 20, 24, 48, 60, 72, 96, 120, 144 hours post dose |
| Residual Area | Extrapolated area (AUC0-inf - AUC0-t)/ AUC0-inf | 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 12, 14, 16, 20, 24, 48, 60, 72, 96, 120, 144 hours post dose |
| Kel | Apparent first - order terminal elimination rate constant calculated from a semi-log plot of the plasma concentration versus time curve, using the method of least square regression. | 6 days |
| t1/2 | Terminal half-life as determined by quotient 0.693/Kel | 6 days |
| D006331 |
| Heart Diseases |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D006571 |
| Heterocyclic Compounds |